Profile data is unavailable for this security.
About the company
Piramal Enterprises Limited (PEL) is an India-based company, which is engaged in providing finance. PEL’s financial services offer a range of financial products and solutions, with wholesale and retail financing. The wholesale lending business provides financing to real estate developers, as well as corporate. Within retail lending, PEL is engaged in building a multi-product platform and offers home loans, loans for small businesses and loans for working capital to its customers. The Company offers India Resurgence Fund (IndiaRF), the distressed asset investing platform, which invests in equity and/or debt across non-real estate sectors. Its financial services also include alternative assets and investments in Shriram Group. It provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector, and funding solutions to infrastructure, renewable energy.
- Revenue in INR (TTM)80.27bn
- Net income in INR-16.84bn
- Incorporated1947
- Employees12.22k
- LocationPiramal Enterprises Ltd10th floor, Piramal TowerGanpatrao Kadam MargLower ParelMUMBAI 400083IndiaIND
- Phone+91 2 230956666
- Fax+91 2 238023084
- Websitehttps://www.piramal.com/businesses/piramal-enterprises/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 104.94bn | 777.00 | 23.07 | 4.53 | 20.38 | 6.19 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
Granules India Ltd | 45.06bn | 4.05bn | 111.91bn | 3.65k | 27.60 | 3.47 | 18.27 | 2.48 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
Jubilant Pharmova Ltd | 67.03bn | 771.00m | 119.75bn | 1.03k | 155.93 | 2.20 | 26.34 | 1.79 | 4.85 | 4.85 | 421.25 | 343.16 | 0.5904 | 1.60 | 7.14 | -- | 0.6404 | 2.96 | 0.7627 | 3.55 | 68.06 | 69.37 | 1.08 | 5.13 | 1.37 | 2.09 | 0.4033 | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Eris Lifesciences Ltd | 20.09bn | 3.92bn | 137.25bn | 3.55k | 35.05 | 5.31 | 23.68 | 6.83 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Sanofi India Ltd | 28.47bn | 5.49bn | 157.50bn | 2.17k | 28.68 | -- | 26.74 | 5.53 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Concord Biotech Ltd | 10.17bn | 3.08bn | 160.12bn | 1.38k | 51.99 | 10.49 | 44.27 | 15.74 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 161.46bn | 947.00 | 99.98 | 22.68 | 91.51 | 12.46 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 174.59bn | 14.59k | 28.34 | 3.62 | 19.63 | 2.80 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | -- | 9.77 | 10.82 | 12.94 | 14.38 | 72.46 | 67.67 | 9.90 | 12.58 | 0.9863 | 11.76 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 183.07bn | 1.17k | 60.89 | 8.93 | 51.61 | 17.41 | 11.81 | 11.81 | 41.36 | 80.56 | 0.4983 | 1.64 | 8.60 | -- | 14.23 | 23.17 | 15.19 | 26.20 | 57.59 | 58.56 | 28.56 | 33.21 | 9.65 | 66.88 | 0.0307 | -- | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Piramal Enterprises Ltd | 80.27bn | -16.84bn | 198.01bn | 12.22k | -- | 0.7429 | -- | 2.47 | -76.51 | -76.51 | 345.53 | 1,187.94 | 0.0965 | -- | 497.33 | -- | -2.02 | 2.57 | -2.05 | 3.16 | 45.17 | 81.98 | -20.97 | 21.59 | -- | -0.0035 | 0.6686 | 26.39 | -3.80 | -7.55 | -116.89 | -- | 12.91 | -18.22 |
Piramal Pharma Ltd | 81.71bn | 178.20m | 208.50bn | 6.30k | 2,631.00 | 2.64 | 27.49 | 2.55 | 0.06 | 0.06 | 65.09 | 59.80 | 0.5478 | 1.53 | 4.15 | -- | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Natco Pharma Ltd. | 39.99bn | 13.88bn | 216.83bn | 3.98k | 15.66 | 3.70 | 13.77 | 5.42 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
Pfizer Ltd | 21.93bn | 5.51bn | 220.92bn | 1.70k | 40.07 | 6.14 | 36.00 | 10.07 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Laurus Labs Ltd | 50.41bn | 1.61bn | 234.47bn | 5.75k | 146.43 | 5.70 | 42.42 | 4.65 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Syngene International Ltd | 34.89bn | 5.10bn | 283.73bn | 6.85k | 55.76 | 6.66 | 30.32 | 8.13 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 287.81bn | 5.10k | 52.78 | 9.84 | 41.65 | 8.26 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Holder | Shares | % Held |
---|---|---|
East Bridge Capital Management L.P.as of 31 Mar 2023 | 16.77m | 7.46% |
The Caisse de d�p�t et placement du Qu�becas of 13 Jun 2023 | 11.63m | 5.18% |
Life Insurance Corporation of India (Investment Portfolio)as of 31 Mar 2023 | 11.58m | 5.16% |
The Vanguard Group, Inc.as of 09 May 2024 | 4.55m | 2.03% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 2024 | 4.48m | 2.00% |
Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 1.60m | 0.71% |
BlackRock Fund Advisorsas of 09 May 2024 | 1.52m | 0.68% |
Dimensional Fund Advisors LPas of 30 Apr 2024 | 1.51m | 0.67% |
ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 1.06m | 0.47% |
SBI Funds Management Ltd.as of 31 May 2024 | 960.77k | 0.43% |